Neuroleptic malignant syndrome: A case report and review of treatment

Hospital Pharmacy

Volumn 32, Issue 4, 1997, Pages 512-518

  Najib, Jadwiga ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

bromocriptine; clozapine; dantrolene; haloperidol; neuroleptic malignant syndrome; risperidone

Indexed keywords

AMANTADINE; AMOXAPINE; BENZATROPINE MESILATE; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; DANTROLENE; DIAZEPAM; DIPHENHYDRAMINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; HYDROXYZINE; LORAZEPAM; LOXAPINE; METOCLOPRAMIDE; MOLINDONE; NEUROLEPTIC AGENT; PARACETAMOL; PROCHLORPERAZINE; PROMETHAZINE; RESERPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; VALPROIC ACID;

ADULT; AUTONOMIC DYSFUNCTION; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTHERMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTOSIS; MALE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; ORAL DRUG ADMINISTRATION; PARANOID SCHIZOPHRENIA; REVIEW;

EID: 0030889203     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Olmsted TR. Neuroleptic malignant syndrome: Guidelines for treatment and reinstitution of neuroleptics. South Med J. 1988;81:888-891.
2. Lazarus A. Neuroleptic malignant syndrome: detection and management. Psychiatr Ann. 1985;15:706-712.
3. Parks-Veal P. Neuroleptic malignant syndrome. Hosp Pharm. 1990;25:121-123, 133.
4. Kornhuber J, Weller M. Neuroleptic malignant syndrome. Curr Opin Neurol. 1994;7:353-357.
5. Nierenberg D, Disch M, Manheimer E, et al. Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clin Pharmacol Ther. 1991;50: 580-586.
6. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50:18-25.
7. Addonizio G, Sklusman VL, Roth SD. Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol Psychiatry. 1987;22:1004-1020.
8. Velamoor VR, Norman RM, Caroff SN et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182:168-173.
9. Pearlman CA. Neuroleptic malignant syndrome: A review of the literature. J Clin Psychopharmacol. 1986;6:257-273.
10. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41: 79-83.
11. Dickey W. The neuroleptic malignant syndrome. Prog Neurobiol. 1991;36:425-436.
12. Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: A study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992;4:265-269.
13. Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16: 425-443.
14. Rosebush P, Stewart T. A prospective analysis of 24 episodes of NMS. Am J Psychiatry. 1989;146:717-725.
15. Connelly MA, Fowler EK. Neurolpetic malignant syndrome. J Am Board Fam Pract. 1992;5:327-331.
16. Parikh AM, Camara EG. Neuroleptic malignant syndrome. Am Fam Physician. 1988;37:296-298.
17. Keck PE, Pope HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: A case-control study. Arch Gen Psychiatry. 1989;46:914-918.
18. Mann SC, Caroff SN, Bleier HR, et al. Lethal catatonia. Am J Psychiatry. 1986;143: 1374-1387.
19. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:324-328.
20. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever: Heterogeneity of the neuroleptic malignant syndrome. Arch Gen Psychiatry. 1986;43:839-848.
21. Rampertaap MP. Neuroleptic malignant syndrome. South Med J. 1986;79:331-336.
22. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 1992;53:56-62.
23. Mueller PS. Neuroleptic malignant syndrome. Psychosomatics. 1985;26:654-662.
24. O'Dwyer AM, Sheppard NP. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psychologic Med. 1993;23:323-326.
25. Sakkas P, Davis JM, Janicak PG, Wang Z. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27:381-384.
26. Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium: A case report. Am J Psychiatry. 1982;139:944-945.
27. Nisijima K, Ishiguro T. Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study. Biol Psychiatry. 1993;33:45-48.
28. Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome: Successful treatment with bromocriptine. JAMA. 1982;249:386-388.
29. Amdurski S, Radwan M, Levi A, et al. A therapeutic trial of amantadine in haloperidol-induced neuroleptic malignant syndrome. J. Clin Psychiatry. 1987;48:69-73.
30. Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED. Bromocriptine treatment of neuroleptic malignant syndrome. J Clin Psychiatry. 1987;48:69-73.
31. Scarlett JD, Zimmerman R, Berkovic SF. Neuroleptic malignant syndrome. Aust NZJ Med. 1983;13:70-73.
32. Lew T, Tollefson G. Chlorpormazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiat. 1983;18:1441-1446.
33. Morris HH, McCormick WF, Reinorz JA. Neuroleptic malignant syndrome. Arch Neurol. 1980;37:462-463.
34. Greenberg LB, Gujavarty K. The neuroleptic malignant syndrome: Review and report of three cases. Comp Psychiat. 1985;26:63-70.
35. Kumar V. A case of neuroleptic malignant syndrome treated with diazepam. Can J Psychiat. 1987;32:815-816.
36. O'Brien P. Neuroleptic malignant syndrome treated with diazepam. Can J Psychiat. 1988;33:780.
37. Miller DD, Sharafuddin MJA, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry. 1991;52:99-101.
38. Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry. 1991;52: 102-104.
39. Daa Gupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry. 1991;52:105-107.
40. Thornberg SA, Ereshefsky L. Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy. 1993;13:510-514.
41. Goates MG, Escobar J. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: Report of a case and results of a clozapine rechallenge. J Clin Psychopharmacol. 1992;12:139-140.
42. Shalev A, Munitz H. The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiat Scand. 1986;73: 337-347.
43. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmac Bull. 1988; 24:25-29.
44. Rosebush P, Stewart TD, Glenberg AJ. Twenty neuroleptic challenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiat. 1989;50:295-298.
45. Slack T, Stoudemire A. Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome. Gen Hosp Psychiat. 1989; 11:365-367.
46. Jessee SS, Anderson GF. ECT in the neuroleptic malignant syndrome: Case report. J Clin Psychiat. 1983;44:186-188.
47. Aizenberg D, Shalev A, Munitz H. The aftercare of the patient with neuroleptic malignant syndrome. Br J Psychiat. 1985; 146:317-318.